(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Alx Oncology Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2026 to be $733,569,507, with the lowest ALXO revenue forecast at $733,569,507, and the highest ALXO revenue forecast at $733,569,507. On average, 3 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,663,992,125, with the lowest ALXO revenue forecast at $781,501,605, and the highest ALXO revenue forecast at $7,301,308,995.
In 2028, ALXO is forecast to generate $9,108,140,706 in revenue, with the lowest revenue forecast at $3,594,907,383 and the highest revenue forecast at $16,353,181,585.